Exemestane vs Naltrexone
FDA Approved vs FDA Approved
avoid Mechanism-based · 75% Both Exemestane and Naltrexone carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Exemestane Naltrexone
Weight 296.40 Da 341.40 Da
Half-life ~24 hours ~4 hours
Type Steroidal aromatase inhibitor (irreversible, suicide inhibitor) Opioid antagonist (C20H23NO4)
Key Benefits
Exemestane
01 Irreversible aromatase inactivation eliminates estrogen rebound upon discontinuation
02 Steroidal structure with mild androgenic activity may offset some low-estrogen side effects
03 Potent estrogen suppression (85-95% reduction in estradiol at full dose)
04 Compatible with tamoxifen (unlike anastrozole, no pharmacokinetic interference)
05 Prevents gynecomastia during testosterone or aromatizable steroid cycles
06 Reduces estrogen-driven water retention, bloating, and blood pressure elevation
07 Oral dosing with once-daily or less frequent administration for cycle support
Naltrexone
01 Broad anti-inflammatory and immunomodulatory effects via OGF-OGFr axis upregulation
02 Reduction in pro-inflammatory cytokines (TNF-alpha, IL-6, IL-12) through TLR4 antagonism
03 Compensatory upregulation of endogenous endorphins and enkephalins (200-300% increase)
04 Improved immune regulation and rebalancing of Th1/Th2/Th17 responses
05 Reduction in chronic pain through central and peripheral opioid system modulation
06 Potential improvement in mood, anhedonia, and overall well-being via endorphin enhancement
07 Extremely well-tolerated with minimal side effects at low doses
08 Low cost, especially as compounded LDN formulation
Side Effects
Exemestane
Joint pain and stiffness (generally less severe than with anastrozole due to mild androgenic activity)
Fatigue and general malaise
Hot flashes or flushing
Mood changes (irritability, flat affect, low mood)
Headache
Increased sweating
Naltrexone
Vivid dreams or unusually intense dreaming - the most frequently reported side effect, typically diminishes over 1-2 weeks
Initial sleep disruption or insomnia during the first week of treatment
Mild nausea, particularly during the first few days
Transient headache during dose initiation or titration
Contraindications
Known hypersensitivity to exemestane or any excipients
Premenopausal women (not indicated and potentially harmful to reproductive function)
Pregnancy or breastfeeding (teratogenic risk)
Severe hepatic impairment
Pre-existing severe osteoporosis or high fracture risk
Concurrent use with other aromatase inhibitors (anastrozole, letrozole)
Current use of opioid medications or active opioid dependence (must be opioid-free 7-10 days minimum)
Acute hepatitis or severe hepatic impairment (primarily relevant at full dose)
Known hypersensitivity to naltrexone
Anticipated need for opioid pain medication (e.g., upcoming surgery - discontinue LDN 3-7 days prior)
Research Evidence
Exemestane Naltrexone
Status FDA Approved FDA Approved
References 5 studies 5 studies
Latest — 2023
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.